Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Alnylam Pharmaceuticals, Inc. before investing.

In this article, we go over a few key elements for understanding Alnylam Pharmaceuticals, Inc.’s stock price such as:

• Alnylam Pharmaceuticals, Inc.’s current stock price and volume
• Why Alnylam Pharmaceuticals, Inc.’s stock price changed recently
• Upgrades and downgrades for ALNY from analysts
• ALNY’s stock price momentum as measured by its relative strength

About Alnylam Pharmaceuticals, Inc. (ALNY)

Before we jump into Alnylam Pharmaceuticals, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer’s disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington’s disease; ALN-5288 for Alzheimer’s disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson’s disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Want to learn more about Alnylam Pharmaceuticals, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Alnylam Pharmaceuticals, Inc..

Alnylam Pharmaceuticals, Inc.’s Stock Price as of Market Close

As of May 15, 2026, 10:16 AM, CST, Alnylam Pharmaceuticals, Inc.’s stock price was $290.420.

Alnylam Pharmaceuticals, Inc. is down 1.03% from its previous closing price of $293.450.

During the last market session, Alnylam Pharmaceuticals, Inc.’s stock traded between $287.360 and $298.000. Currently, there are approximately 132.89 million shares outstanding for Alnylam Pharmaceuticals, Inc..

Alnylam Pharmaceuticals, Inc.’s price-earnings (P/E) ratio is currently at 74.3, which is high compared to the Biotechnology industry median of 20.6. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Alnylam Pharmaceuticals, Inc. Stock Price History

Alnylam Pharmaceuticals, Inc.’s (ALNY) price is currently down 6.16% so far this month.

During the month of May, Alnylam Pharmaceuticals, Inc.’s stock price has reached a high of $311.880 and a low of $284.280.

Over the last year, Alnylam Pharmaceuticals, Inc. has hit prices as high as $495.550 and as low as $266.180. Year to date, Alnylam Pharmaceuticals, Inc.’s stock is down 26.97%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Alnylam Pharmaceuticals, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of May 14, 2026, there were 0 analysts who downgraded Alnylam Pharmaceuticals, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Alnylam Pharmaceuticals, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Alnylam Pharmaceuticals, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Alnylam Pharmaceuticals, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Alnylam Pharmaceuticals, Inc. (ALNY) by visiting AAII Stock Evaluator.

Relative Price Strength of Alnylam Pharmaceuticals, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 14, 2026, Alnylam Pharmaceuticals, Inc. has a weighted four-quarter relative price strength of -2.61%, which translates to a Momentum Score of 53 and is considered to be Average.

Want to learn more about how Alnylam Pharmaceuticals, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Alnylam Pharmaceuticals, Inc. Stock Price: Bottom Line

As of May 15, 2026, Alnylam Pharmaceuticals, Inc.’s stock price is $290.420, which is down 1.03% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Alnylam Pharmaceuticals, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.